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Background: Systematic reviews of randomized, controlled trials in patients with influenza 
suggest a lack of evidence about the effects of antiviral therapy on several patient-important 
outcomes of influenza.
Purpose: To systematically review observational studies for benefits and harms of oseltamivir, 
zanamivir, amantadine, or rimantadine in the treatment of influenza.
Data Sources: MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, 
CINAHL, SIGLE, the Chinese Biomedical Literature Database, Panteleimon, and LILACS up to 
November 2010; contact with pharmaceutical companies; and reference lists.
Study Selection: Observational studies in any language that compared single antiviral therapy 
with no therapy or other antiviral therapy, or that had no comparator, for influenza or influenza-
like illness.
Data Extraction: Two independent investigators extracted data. Confidence in the estimates of 
the obtained effects (quality of evidence) was assessed by using the Grading of Recommendations 
Assessment, Development, and Evaluation approach.
Data Synthesis: 74 studies fulfilled the inclusion criteria. Meta-analyses of the few studies 
providing effects with adjustment for confounders suggest that, in high-risk populations, oral 
oseltamivir may reduce mortality (odds ratio, 0.23 [95% CI, 0.13 to 0.43]; low-quality evidence), 
hospitalization (odds ratio, 0.75 [CI, 0.66 to0.89]; low-quality evidence), and duration of 
symptoms (33 hours [CI, 21 to 45 hours]; very low–quality evidence) compared with no treatment. 
Earlier treatment with oseltamivir was generally associated with better outcomes. Inhaled 
zanamivir may lead to shorter symptom duration (23 hours [CI, 17 to 28 hours]; moderate-quality 
evidence) and fewer hospitalizations (odds ratio, 0.66 [CI, 0.37 to1.18]) but more complications 
than no treatment. Direct comparison of oral oseltamivir and inhaled zanamivir suggests no 
important differences in key outcomes. Data from 1 study suggest that oral amantadine may 
reduce mortality and pneumonia associated with influenza A. No included study evaluated 
rimantadine.
Limitations: Mortality was assessed in high-risk patients, and generalizability is limited. The 
overall body of evidence is limited by risk for confounding and selection, reporting, and 
publication bias.
Conclusion: Therapy with oral oseltamivir and inhaled zanamivir may provide a net benefit over 
no treatment of influenza. However, as with the randomized trials, the confidence in the estimates 
of the effects for decision making is low to very low.
Primary Funding Sources: World Health Organization and Mc-Master University.
Influenza virus infections result in major health and economic burdens worldwide. The 
World Health Organization (WHO) estimates that the average global burden of 
interpandemic influenza is approximately 1 billion cases of influenza, 3 to 5 million cases of 
severe illness, and 300 000 to 500 000 deaths annually (1). Among the 90 million influenza 
cases in children younger than 5 years in 2008, an estimated 28 000 to 111 500 children died 
of influenza-associated lower respiratory tract infection (2). Most cases of influenza are self-
limited, and prevention through annual influenza vaccination may be an effective strategy. 
However, antiviral treatment with neuraminidase inhibitors (oseltamivir or zanamivir) or M2 
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ion channel blockers (amantadine or rimantadine) is used to reduce signs and symptoms and 
to prevent hospitalizations or death in patients with severe disease.
In February 2010, WHO updated its guidelines for the treatment of influenza, which are 
used worldwide (3). However, evidence about the effects and safety of antiviral agents 
continues to increase and, in 2012, Jefferson and colleagues (4) updated a review of the 
randomized, controlled trial (RCT) literature to inform treatment decisions. Data from only 
25 of 67 RCTs could be used for the analyses. The investigators found that oral oseltamivir 
reduced the duration of symptoms by around 21 hours from a median of 160 hours in the 
placebo groups but had no effect on hospitalizations (odds ratio [OR], 0.95 [95% CI,0.57 to 
1.61]) on the basis of 7 studies with a median event rate of 0.84% in the placebo group.
In theory, the best evidence for health care decisions comes from RCTs. However, the 
quality of evidence across these RCTs has raised concerns (4), due in part to the lack of 
precision in the effect estimates; the lack of evidence for certain patient-important health 
outcomes, such as death; and poor assessment and reporting of other outcomes, such as 
adverse events. In addition, questions remain about the effects of antiviral agents to treat 
influenza A or B and in specific groups, such as hospitalized or immunocompromised 
patients.
Observational studies may provide important additional information or higher-quality 
evidence than available RCTs for certain elements of the health care problem, such as 
specific populations, administration modes, and outcomes (such as mortality). We reviewed 
the evidence from observational studies to inform WHO guidelines and the WHO essential 
medicine list about the antiviral treatment of influenza.
METHODS
Our primary objective was to evaluate the effectiveness and safety of neuraminidase 
inhibitors (oseltamivir and zanamivir) for treatment of influenza (A or B) virus infection, 
and M2 ion channel blockers or adamantanes (amantadine and rimantadine) to treat 
influenza A virus infections. The original research questions were coordinated with WHO. 
We developed a protocol that included the following criteria.
Data Sources and Searches
We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, 
CINAHL, SIGLE, the Chinese Biomedical Literature Database, Panteleimon, and LILACS 
for relevant studies up to 16 November 2010. We used no restrictions by language or study 
design (the Appendix, available at www.annals.org, lists our search strategies). We contacted 
the WHO, 8 pharmaceutical companies, the U.S. Food and Drug Administration, the 
European Medicines Agency, the U.S. Centers for Disease Control and Prevention, and the 
European Centre for Disease Prevention and Control for unpublished observational data. We 
also reviewed reference lists of relevant studies and other reviews for studies.
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Study Selection
Investigators independently screened all citations by title and abstract in pairs. We then 
retrieved the full text of these studies, and 2 investigators independently screened them for 
inclusion. Disagreements about inclusion were resolved by discussion or by consulting a 
third investigator.
We followed a priori study eligibility criteria for study selection. We included any 
observational study that compared any of the antiviral drugs with no antiviral treatment or 
with another antiviral drug for the treatment of laboratory-confirmed influenza or influenza-
like illness (not confirmed) and any observational study with no independent comparison 
group if studies with an independent comparison group were not available. The antiviral 
drugs were oseltamivir, zanamivir, amantadine, and rimantadine in any dose or by any route, 
with the exception of intravenous administration. We also evaluated studies that compared 
early antiviral treatment with late antiviral treatment by using 48 hours from the onset of 
symptoms or treatment as the reference point between early and late treatment. We excluded 
RCTs, studies with fewer than 25 patients, and studies evaluating antiviral chemopro-
phylaxis of influenza. We included studies in all populations with influenza or influenza 
like-illness.
We determined a priori to report on the following outcomes because they were judged to be 
important or critical for decision making: death; hospitalization; intensive care unit (ICU) 
admission, mechanical ventilation and respiratory failure; duration of hospitalization; 
duration of signs and symptoms; time to return to normal activity; complications; critical 
adverse events, such as major psychotic disorders, encephalitis, stroke, or seizure; important 
adverse events, such as pain in extremities, clonic twitching, body weakness, or 
dermatologic changes (such as urticaria or rash); influenza viral shedding; and emergence of 
antiviral resistance.
Data Extraction and Quality Assessment
Two independent investigators extracted data from the included studies by using a pretested 
electronic form. We extracted details of the study design, limitations in study design or 
execution (risk of bias), the country where the study was conducted, patient characteristics, 
method of influenza diagnosis, influenza characteristics (including virus strain, outbreak 
setting, and disease severity), intervention characteristics (including drug type, dose, 
duration of use, start time, and co-interventions), study funding, and outcomes. When 
abstracted data differed, the investigators resolved these differences by consensus. We used 
the Newcastle–Ottawa Scale (5) to assess the risk of bias of the included case–control and 
cohort studies on the basis of selection of study groups, comparability of groups, and 
ascertainment of the exposure or outcome of interest.
Two trained investigators with experience in using the GRADE (Grading of 
Recommendations Assessment, Development, and Evaluation) approach assessed the 
confidence in the estimates of effect of the body of evidence (quality of evidence) by 
outcome and produced the draft evidence profiles according to GRADE (6, 7). The 
completed evidence summaries and GRADE assessments were discussed by several 
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investigators and reviewed by the senior investigator. Factors that affect the confidence in the 
estimate of effect include risk of bias (also known as detailed design and study limitations), 
imprecision, indirectness (directness in the GRADE approach includes generalizability and 
applicability), inconsistency of results (heterogeneity), publication bias, dose–effect 
responses, magnitude of effect, and issues of residual plausible confounding. The confidence 
in the estimate of effect is categorized into 4 levels, ranging from very low to high.
Data Synthesis and Analysis
We conducted meta-analyses of dichotomous outcomes with random-effects models by 
using the odds ratio (OR) and conducted meta-analyses of continuous outcomes in Review 
Manager, version 5.1 (The Nordic Cochrane Center and the Cochrane Collaboration, 
Copenhagen, Denmark) by using mean differences or standardized mean differences 
(SMDs). Standardized mean differences were used to pool effects across studies when 
outcomes (such as duration of symptoms of expected different length) were measured or 
reported differently in these studies. To facilitate interpretation of the SMDs, we back-
transformed them into common units based on the mean across studies for these outcomes. 
We pooled the data by using ORs when the number of events were available and pooled the 
logarithm of the ORs weighted by the inverse variance when events were not available. 
Analyses were performed separately for studies that provided adjusted as opposed to crude 
ORs.
For studies that reported events for certain outcomes in only 1 treatment group (for example, 
adverse events for the treatment group but no comparison group), we combined proportions 
weighted by the generic inverse variance. We grouped adverse events and complications 
according to a priori ratings of importance (critical, important, or not important) according 
to the GRADE approach(8). For these outcomes, we calculated a rate ratio and pooled the 
logarithm of the rate ratios weighted by the generic inverse variance.
When data were available, we performed a priori subgroup analyses by age (1 to 15 years, 
16 to 65 years, and ≥65 years), risk for complications (patients at low risk, patients admitted 
to the ICU, and immunocompromised patients), influenza type (A or B), laboratory-
confirmed influenza versus influenza-like illness (not confirmed), pandemic or 
interpandemic influenza, dose of antiviral agent, and potential for funding conflict. 
Heterogeneity was assessed by using the chi-square test and quantified by using the I2 
statistic (9). If results showed substantial heterogeneity I2 >60%), we explored heterogeneity 
on the basis of the a priori hypotheses. Evidence summaries were prepared for each research 
question by using the GRADE Profiler (GRADEpro), version 3.6 (McMaster University, 
Hamilton, Ontario, Canada).
Role of the Funding Source
This review was commissioned and partially funded by WHO as an independent review. It 
was conducted as a collaboration of researchers from the McMaster Healthcare Grading and 
Recommendations Center as part of the activity of the McMaster WHO collaborating center 
for evidence-informed policy and the Norwegian Knowledge Center for the Health Services. 
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The protocol for the review was discussed with WHO staff, and WHO staff provided 
references to studies that were assessed for inclusion.
RESULTS
Literature Flow
We identified 12 188 citations from the electronic search of the databases and 27 articles by 
reviewing reference lists of relevant papers and studies sent to us by pharmaceutical 
companies (Hoffman-La Roche, Basel, Switzerland, and GlaxoSmithKline, Brentford, 
Middlesex, United Kingdom) in response to our request for data (Appendix Figure, available 
at www.annals.org). The U.S. Food and Drug Administration provided us with the same 
postmarketing adverse event data described by Jefferson and colleagues in 2010 (10), which 
lists adverse event reports generated worldwide. However, these data were not suitable for 
our analyses because no denominator was provided for the population. We obtained the full 
text of 920 articles and included 74 articles after full-text review. We translated articles from 
Chinese, French, Japanese, Russian, and Spanish.
Oseltamivir
We found 51 observational studies that compared the effects of oral oseltamivir with those of 
no antiviral therapy (11–61). Only a few studies (13, 14, 20, 24, 37, 41, 45,48) adjusted for 
confounders, such as age and comorbid conditions, when reporting mortality, 
hospitalization, and complications, and we rated these studies as having low risk for 
observational study bias. Many of the other studies measuring complications drew patient 
data from health insurance administrative databases that listed unconfirmed diagnoses. 
Substantial reporting and publication bias may exist for several of the evaluated outcomes 
(in particular, complications) because the studies were funded by for-profit organizations. 
Table 1 summarizes the findings and the quality of the evidence for oral oseltamivir 
compared with no antiviral therapy, and the Figure shows the summary results of the meta-
analyses. The Supplement Figures (available at www.annals.org) show the related forest 
plots and those of all other analyses.
Three studies reporting on mortality in hospitalized patients (24, 37, 41) adjusted for age, 
comorbid conditions, or other prognostic factors, but no study described the reasons for 
administering oseltamivir to selected patients. The pooled OR (0.23 [CI, 0.13 to 0.43]) 
suggests that oral oseltamivir may reduce mortality compared with no antiviral therapy, 
translating to an absolute risk reduction of 17.2% in this high-risk population. The overall 
grade for the quality of evidence was low. A pooled estimate of unadjusted effects from 9 
studies (16, 22, 27, 29, 36, 37, 42, 52, 60) enrolling 1557 patients resulted in a more modest 
reduction in mortality (OR, 0.51 [CI, 0.23 to 1.14]). Similar results were found in studies 
that could not be pooled: One study (33) reported an adjusted hazard ratio of 0.27 (CI, 0.13 
to 0.55) in 754 patients, and another (47) reported a statistically nonsignificant difference in 
mortality in approximately 75 000 patients recruited primarily in outpatient settings.
Meta-analysis of data from 4 studies (13, 20, 45, 48) enrolling 150 710 patients showed that 
oral oseltamivir may reduce hospitalization in outpatients (OR, 0.75 [CI,0.66 to 0.89]). 
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Although all 4 studies adjusted for age, only 1 study (13), with 40 704 patients, adjusted for 
other important prognostic factors, such as comorbid conditions and geographic region. In 
absolute terms, approximately 12 of every 1000 patients require hospitalization and oral 
oseltamivir can reduce this by 3 to 9 per 1000 patients. Meta-analysis of data from 6 studies 
(30–32, 50, 55, 56) suggests that oral oseltamivir reduces the duration of fever by 
approximately 33 hours (CI, 21 to 45 hours) from onset of symptoms compared with no 
antiviral therapy (SMD, −0.91 [CI, −1.25 to −0.57]). Studies that could not be pooled also 
showed a reduction in the duration of signs and symptoms with oral oseltamivir (43, 58). 
The results of 5 studies (12, 21, 29, 36, 58) suggest that oral oseltamivir may result in fewer 
adverse events, such as neuropsychiatric events, than no antiviral therapy (rate ratio, 0.76 
[CI, 0.70 to 0.81]). At 6 months, 1 study (40) found a reduction in risk for stroke and 
transient ischemic attacks in patients younger than 65 years who received oral oseltamivir 
(adjusted hazard ratio, 0.66 [CI, 0.56 to 0.77]), but no statistically significant difference in 
patients aged 65 years or older. Evidence also suggested that oral oseltamivir had fewer 
complications, such as pneumonia (adjusted OR, 0.83 [CI, 0.59 to 1.16]) (13, 45, 48), otitis 
media (adjusted OR, 0.75 [CI, 0.64 to 0.87]) (13, 48), or any recurrent cardiovascular 
outcome (adjusted OR, 0.58 [CI,0.31 to 1.10]) (14, 47).
The pooled incidence of resistance to oseltamivir across 5 studies (25, 26, 28, 54, 57) was 30 
per 1000 patients receiving oral oseltamivir (CI, 10 to 60 per 1000 patients), and influenza 
virus was detectable in 330 per 1000 patients (CI, 280 to 370 per 1000 patients) 
approximately 5 days after treatment with oral oseltamivir (32, 35, 38, 39, 55, 56). No study 
compared the persistence of influenza virus between patients who received oseltamivir and 
those who did not.
A subgroup analysis of 9 studies showed differences for seasonal versus pandemic influenza 
(OR, 0.29 [CI, 0.17 to0.52] vs. 0.93 [CI, 0.47 to 1.84]; P for the difference = 0.011) but not 
for disease severity or age (Supplement Table 1, available at www.annals.org). Subgroup 
analyses also showed statistically significant effects in children compared with adults for 
pneumonia and otitis media. Only for pneumonia did we observe a significantly larger effect 
for oral oseltamivir in laboratory-confirmed influenza versus influenza-like illness.
We found 16 observational studies (17, 28, 34, 38, 43, 52, 60, 62–70) that evaluated the 
effects of starting treatment of influenza with oral oseltamivir within 48 hours of symptom 
onset versus after 48 hours (Table 2). However, none of these studies, including 8 studies 
that assessed mortality, appropriately adjusted for such confounders as age or disease 
severity. The results were also imprecise for the outcomes of mortality, duration of 
hospitalization, and signs and symptoms.
Mortality, hospitalizations, ICU admission, and respiratory failure were reduced when oral 
oseltamivir was received within 48 hours compared with later treatment (Table 2). Two 
studies (33, 69), which could not be included in the meta-analysis, reported little or no 
difference in mortality when therapy with oral oseltamivir began early. Two other studies 
showed positive effects on the duration of hospitalization with early treatment: A Centers for 
Disease Control and Prevention report (62) showed a reduction of 24 hours (CI, 0 to 48 
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hours), and another study(33) showed an increased duration with late treatment (adjusted 
hazard ratio, 1.28 [CI, 1.04 to 1.57]).
Three studies (28, 43, 70) reported inconsistent effects of early versus late treatment on the 
duration of signs and symptoms. One study (28) reported an increase of 6 hours (CI, 6 fewer 
to 18 more hours), another (43) found a reduction (median, 5 days with early vs. 9 days with 
late treatment; P= 0.01), and the third (70) found that the duration of fever may be 1.4 times 
longer. Critical complications may not differ between early and late treatment with oral 
oseltamivir (OR, 1.2 [CI, 0.44 to 3.36]) (63, 70). Three studies (38, 67, 70) suggested that 
early treatment reduces the duration of viral shedding. Overall, the effects may vary across 
specific populations. For example, the pooled unadjusted OR for mortality across all 
populations with early treatment compared with later treatment was0.39 (CI, 0.12 to 1.30) 
(43, 52, 60, 63–66, 68). The corresponding pooled unadjusted ORs were 1.47 (CI, 0.87 to 
2.50) in low-risk patients and 0.03 (CI, 0 to 0.21) in pregnant women (Supplement Table 2, 
available at www.annals.org, provides subgroup analyses) (43, 52, 60, 64, 65, 68, 69). 
Patients with confirmed influenza seemed to benefit less from earlier treatment than did 
patients with unconfirmed influenza (OR, 0.67 [CI, 0.25 to 1.76] vs.0.03 [CI, 0 to 0.21]; P 
for test of interaction = 0.005) (Supplement Table 2).
Zanamivir
We found 5 observational studies (31, 49, 52, 56, 71) and 2 surveys (72, 73) that compared 
inhaled zanamivir with no antiviral therapy among persons treated as outpatients. One study 
(52) provided data for mortality, hospitalization, and ICU admissions in pregnant women 
who did not all have confirmed influenza. Complications from presumed viral infection were 
measured in patients with influenza-like illness. Only the duration of symptoms was judged 
as moderate-quality evidence on the basis of a meta-analysis of 3 studies enrolling 770 
patients. However, the overall confidence in the estimates of effect was very low for all other 
outcomes because none of the studies adjusted for potential confounders and results for most 
outcomes were imprecise. Table 3 summarizes the findings of the studies and the quality of 
the evidence.
Two studies (52, 71) found that patients with laboratory-confirmed influenza or influenza-
like illness who receive inhaled zanamivir may be less likely to be hospitalized than those 
who receive no antiviral therapy (OR, 0.66 [CI, 0.37 to 1.18]). Pooled results from 3 studies 
(39, 49, 56) indicate that inhaled zanamivir reduced the duration of symptoms by 
approximately 23 hours (CI, 17 to 28 hours) on the basis of a large SMD (−0.94 [CI, −1.21 
to −0.66]). One study in outpatients (71), which could not be included in the meta-analysis, 
also showed a 45% reduction in the duration of illness and a 40% reduction in the severity of 
symptoms with inhaled zanamivir. Data from 2 surveys about symptom relief and duration 
of symptoms (72, 73) reported that most patients had fewer symptoms after 2 days. In 
patients with influenza-like illness, more may experience complications, such as otitis media 
(OR, 1.19 [CI, 0.67 to 2.14]), respiratory disease (OR, 1.17 [CI, 0.98 to 1.39]), or all 
outpatient complications (OR, 1.2 [CI, 1.02 to 1.40]) with inhaled zanamivir(71). A study in 
pregnant women (52) suffered from imprecision and showed no effect of inhaled zanamivir 
on ICU admission (OR, 1.18 [CI, 0.29 to 4.83]). In addition, no study clearly reported on 
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adverse events. We found no observational studies that compared early versus late treatment 
of influenza with inhaled zanamivir and did not identify statistically significant subgroup 
effects (Supplement Table 3, available at www.annals.org).
Oseltamivir Versus Zanamivir
We found 8 observational studies (31, 49, 52, 56, 74–77) that directly compared oral 
oseltamivir with inhaled zanamivir. No study adjusted for important potential confounders 
(age or comorbid conditions). All outcomes were graded as very low quality because of risk 
of bias or imprecision. Table 4 shows the GRADE evidence profile, and Supplement Table 4 
(available at www.annals.org) shows the results of preplanned subgroup analyses.
A small study in pregnant women (52) reported an OR of 1.27 (CI, 0.07 to 22.16) for death 
with oseltamivir. Two other small studies (75, 76) were conducted in outpatient populations 
with mild uncomplicated influenza but did not report on deaths. The combined results of 5 
Japanese studies in patients with confirmed influenza (31, 49, 55, 74, 75) suggest that 
inhaled zanamivir may be associated with a slightly shorter symptom duration than oral 
oseltamivir (7 hours [CI, 2 to 12 hours]; SMD, 0.26 [CI,0.07 to 0.45]). However, data from 
another study (76), which could not be pooled, reported no statistically significant difference 
in duration of symptoms. The 2 treatments did not differ for hospitalization (OR, 1.4 [CI, 
0.45 to4.35]) or ICU admissions (OR, 0.58 [CI, 0.16 to 2.18]) in a study enrolling pregnant 
women (52) or for critical adverse events in 1 study of outpatients with confirmed influenza 
(rate ratio, 2.90 [CI, 0.37 to 23.05]) (31). Another study (56) showed no statistically 
significant difference in influenza viral RNA detection after 5 days of treatment (OR, 3.05 
[CI, 0.78 to 11.96]).
Amantadine and Rimantadine for Influenza A
We found 6 observational studies evaluating influenza seasons from 1988 to 2006: Three 
studies (30, 78, 79) compared oral amantadine with no antiviral therapy for influenza A, and 
3 (80–82) evaluated oral amantadine only (no independent comparison group), providing 
incidence data for time to alleviation of symptoms and adverse events. One of these studies 
(82) measured amantadine resistance after treatment in a sample of 111 children in an 
outpatient setting. Taken together, the quality of this body of evidence is very low because of 
the serious risk of bias and imprecise results. Supplement Table 5 (available at 
www.annals.org) summarizes our findings and the quality of the evidence.
One study (78) found that receiving oral amantadine may reduce mortality (OR, 0.04 [CI, 0 
to 0.73]) and pneumonia (OR, 0.76 [CI, 0.38 to 1.53]), but time to alleviation of symptoms 
did not significantly differ between oral amantadine and no antiviral therapy. Another study 
(30) showed a shorter duration of hospitalization with oral amantadine than with no antiviral 
therapy. Pooled incidence rates from 3 studies (30, 80, 81) showed a time to alleviation of 
symptoms of 64 hours (CI, 62 to 65 hours). One study (79) reported that 15 of 45 
hospitalized adults (33%) with confirmed influenza A developed pneumonia and 21 of 55 
adults (38%) were admitted to the ICU because of respiratory failure while receiving oral 
amantadine. Pooled incidence rates for adverse events in patients receiving oral amantadine 
suggested that adverse events were nearly absent (30, 81). For resistance, 1 study found that 
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28% (CI, 20% to 36%) of children were infected with influenza A virus that was resistant to 
amantadine after treatment (82).
We found 1 observational study (80) comparing early versus late treatment with oral 
amantadine. The study included 676 patients with influenza A who received oral 
amantadine, 50 mg twice daily, for 5 days as outpatients. The mean duration of fever was 
52.5 hours (SD, 26.6) after onset of symptoms when amantadine was given between 0 and 
12 hours; 63.6 hours (SD, 24) when given between 13 and 24 hours; and 76 hours (SD, 25.9) 
when given between 25 and 48 hours. Duration of fever was significantly shorter in the 0- to 
12-hour group than in the 13-to 24-hour or 25- to 48-hour groups and also shorter in the 13- 
to 24-hour than in the 25- to 48-hour group.
We found no studies that compared oral rimantadine with no antiviral therapy. However, 2 
studies (83, 84) evaluated the use of oral rimantadine within 24 hours versus after 24 to 48 
hours in patients with influenza A(H1N1) virus infection in outpatient settings during the 
1979 to 1981 seasons and outpatients with influenza-like illness during the reemergence of 
influenza A(H1N1) virus in 1977. Meta-analysis suggested a reduced risk for complications 
with oral rimantadine provided within 24 hours (OR,0.05 [CI, 0.01 to 0.38]). We found no 
studies comparing oral amantadine with oral rimantadine to treat influenza A.
DISCUSSION
Our systematic review summarizes the evidence from 74 observational studies about the 
pharmacologic treatment of influenza with antivirals. Despite low to very low confidence in 
the estimates of effect, this review must be viewed in the context of the information available 
from RCTs and the substantial burden of influenza worldwide. Many of the outcomes for 
which we summarized the evidence have not been assessed in RCTs; in addition, the body of 
evidence from RCTs suffers from even greater imprecision than we found in these 
observational studies. For example, Jefferson and colleagues (4) did not report on mortality 
because no events were reported in the RCTs. Furthermore, the studies we identified 
reported on more than 1600 hospitalizations for more than 150 000 patients, compared with 
the 62 events in 4693 patients in Jefferson and colleagues’ systematic review of RCTs (4).
Our findings indicate that the use of oral oseltamivir to treat influenza may provide net 
benefit by reducing mortality and the duration of symptoms and complications of influenza. 
Jefferson and colleagues (4) also showed that oseltamivir shortened the duration of 
symptoms and complications of influenza, such as asthma. The pooled rate of 
hospitalization in patients not receiving oseltamivir was similar in the 2 reviews (0.8% vs. 
1.2%), but we observed a large, precise effect of oseltamivir on hospitalization (OR,0.75 [CI, 
0.66 to 0.86]). This effect is still compatible with the imprecise estimate from the RCTs 
(OR, 0.95 [CI, 0.57 to 1.61]) (4). In our review, inhaled zanamivir reduces signs and 
symptoms, but we judged the overall confidence in the estimates of effect to be very low 
because of the imprecise and possibly biased data on mortality and hospitalization. A direct 
comparison between oral oseltamivir and inhaled zanamivir in 8 studies showed that 
zanamivir may have a slight advantage in shortening the duration of signs and symptoms. 
The evidence about the use of oral amantadine is sparse but may suggest a benefit from 
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using this agent to treat drug-sensitive influenza A virus infection. The evidence also 
suggests that earlier treatment with antivirals (within 48 hours) may be of greater benefit 
than later treatment.
The strengths of our review include the comprehensive search, attempts to identify 
unpublished data, inclusion of studies reported in languages other than English, and detailed 
assessment of the factors that influence the confidence in the results across questions and 
studies. It adds data on interventions (such as early vs. late treatment), outcomes (such as 
mortality, hospitalizations, and complications), and subgroups (such as 
immunocompromised patients and pregnant women) that are not available from RCTs.
Our review has limitations, relating to the evidence itself, that require attention for both 
interpreting the results and conducting future research. Potential bias reduces the confidence 
in the estimates of effect. Many of the identified studies had a high risk for observational 
study bias due to the lack of control for confounders and covariates (such as the lack of 
adjustment for age or comorbid conditions). For example, of the entire body of evidence on 
inhaled zanamivir, only the estimate for the “duration of signs and symptoms” is based on 
study results that were adjusted for these potential confounders. Confounding by indication 
(a greater likelihood that sicker patients will be treated) could therefore reduce effects based 
on analyses that are not adjusted or are insufficiently adjusted; however, investigators or 
clinicians may also select healthier patients for treatment to reduce potential adverse effects 
of antivirals, which could bias the results in favor of treatment. Greater emphasis should be 
placed on data from adjusted meta-analyses. However, to provide a comprehensive view of 
the available evidence, we present pooled results from the adjusted and the unadjusted 
studies separately.
Even when adjusted analyses were available, we could not always assess whether the authors 
considered all pertinent variables or whether even optimal adjustment would permit valid 
comparisons between treated versus untreated patients in these studies. In addition, for some 
outcomes, such as death in the oseltamivir studies, the results may apply only to hospitalized 
patients because the data were derived in this patient group. Reporting and publication bias 
remain of particular concern in systematic reviews of observational studies (85). Another 
limitation of our study is that we performed our literature search more than 1 year ago and 
did not assess several recent published observational studies of neuraminidase inhibitor 
treatment (86–88). Two additional recently published Cochrane reviews evaluated 
neuraminidase inhibitors in children and adamantanes for influenza A in children and 
elderly patients, but they do not address most of the patient-important outcomes we describe 
(89, 90).
The included studies focused on antiviral treatment of drug-sensitive influenza virus 
infections; therefore, caution should be used when applying these results to the current 
treatment of circulating influenza viruses, which are generally resistant to amantadine and 
rimantadine, or in the future, when the prevalence of antiviral-resistant viruses could 
increase substantially and unpredictably. Concerns have been raised about the increasing 
prevalence of oseltamivir resistance among circulating influenza A(H1N1)pdm09 virus 
strains (91, 92). The development of guidelines based on our review will require judgments 
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about the applicability of the results to populations that may be infected with resistant 
influenza virus.
Despite these limitations, our summary of the evidence provides information that is not 
available in systematic reviews of RCTs. The potential positive effect of earlier rather than 
later administration of oseltamivir on death in hospitalized patients and the suggestion that 
pregnant women, children, and immunocompromised patients may also benefit from 
treatment are among the key contributions of our study. We also found moderate-quality 
evidence that inhaled zanamivir reduces signs and symptoms more than no treatment.
In summary, although we have identified important evidence supporting a role for antivirals 
in the treatment of influenza, attention must be paid when this evidence is applied because of 
the various sources of bias. We need high-quality evidence from randomized trials that 
address patient-important outcomes and include hospitalized patients with influenza. This 
requires trial preparedness and collaboration among large organizations to implement large 
RCTs during influenza epidemics, but given the burden caused by influenza, this should be 
achievable and desirable. Observational studies can supplement this evidence by 
contributing data about special populations, adverse effects, and rare harms. However, such 
studies should minimize selection bias; be prospectively designed, permitting data collection 
for all relevant prognostic factors; and include standardized and validated assessments of 
adverse events that can be summarized in systematic reviews. Studies should also be 
prospectively registered to reduce reporting and publication bias (93). Ideally, RCTs and 
observational studies should also perform serial virologic sampling to correlate with and 
complement clinical data collection. In the meantime, the available data will inform 
guidelines and reimbursement decisions. These data suggest that oral oseltamivir could 
provide a net benefit in the treatment of patients with influenza, including a sizable 
reduction in mortality in hospitalized patients, although our confidence in these effects is 
low.
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APPENDIX:: SEARCH STRATEGIES
EMBASE (1980 to Week 452 010), MEDLINE In-Process and Other 
Nonindexed Citations, MEDLINE (1950 to 16 November 2010), the Cochrane 
Library databases, Chinese Biomedical Literature Database, and 
Panteleimon (to November 2010)
1. influenza$.mp.
2. amantadine.mp.
3. oseltamivir.mp.
4. zanamivir.mp.
5. rimantadine.mp.
6. (aminoadamantane or adamantane or symmetrel or flumadine or tamiflu or 
relenza).tw.
7. neuraminidase inhibitor$.tw.
8. (m2 and (inhibitor$ or ion)).tw.
9. or/2–8
10. 1 and 9
SIGLE (to November 2010)
(influenza*) AND (amantadine or oseltamivir or zanamivir or rimantadine or 
aminoadamantane or adamantane or symmetrel or flumadine or tamiflu or relenza or 
neuraminidase inhibitor*)
CINAHL (1981 to November 2010)
S3. S1 and S2
S2. TX (amantadine or oseltamivir or zanamivir or rimantadine) or MW antiviral agents or 
TX (aminoadamantane or adamantane or symmetrel or flumadine or tamiflu or relenza) or 
TX neuraminidase inhibitor* or TX (m2 and (inhibitor$ or ion))
S1. TX influenza*
LILACS (to November 2010)
“INFLUENZA HUMANA/DT” or “INFLUENZA HUMANA/PC” or “INFLUENZA 
HUMANA/TH” and amantadine or oseltamivir or zanamivir or rimantadine or 
aminoadamantane or adamantane or symmetrel or flumadine or tamiflu or relenza [Words]
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Appendix Figure. 
Summary of evidence search and selection.
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Context
Antiviral therapy may reduce complications and mortality associated with influenza.
Contribution
This review of 74 observational studies found that oral oseltamivir may reduce mortality 
in high-risk populations compared with no treatment. Either oral oseltamivir or inhaled 
zanamivir might reduce hospitalizations and symptom duration.
Caution
The studies were probably biased because of confounding. Neither costs nor targeting 
strategies were evaluated. The studies focused on drug-sensitive infections, so the results 
may not be applicable if resistant viruses are prevalent.
Implication
Antivirals might improve outcomes in some situations, but more evidence is needed to 
guide decision making about when and in whom to use particular agents.
—The Editors
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Figure. 
Random-effects meta-analysis of oral oseltamivir versus no antiviral therapy based on 
studies that provided adjusted effect measures.
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